Achieve Life Sciences, Inc. (ACHV)
NCM · Healthcare · Biotechnology
$5.52
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$566.7M
Shares Outstanding
102.7M
Exchange
NCM
Currency
USD
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -12.6M | -14.7M | -14.7M | -10.5M |
| Net Income | -12.7M | -14.4M | -14.7M | -10.2M |
| Diluted EPS | $-0.37 | $-0.28 | $-0.28 | $-0.19 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -40.8M | -27.2M | -39.1M | -54.9M |
| Net Income | -42.4M | -29.8M | -39.8M | -54.6M |
| Diluted EPS | $-4.00 | $-1.50 | $-1.24 | $-1.25 |